Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesBiovie Inc

Biovie Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.33 USD 0.12 ( 9.92%)
Last update at 2026-11-06T21:00:00Z
VOLUME
174072
Market Cap
11.91M

Momentum Score

…

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.23
Low
1.38
High
52 Week Price Range
1.06
Low
13.20
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Biovie Inc (BIVI) is limited and filings do not provide a clear description of its core operations. Long-term growth may depend on executing strategic plans, securing financing, and achieving any product or regulatory milestones it discloses, which could support revenue if realized.

The most important risks are execution and financing risk, limited public disclosure and likely low liquidity, plus regulatory or operational uncertainty that could materially affect prospects.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.21
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.02
ROE
-80.74%
Net Debt
-17.19M
ROCE
-89.23%
Diluted EPS TTM
-3.28

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -17.54M -32.12M -50.26M -26.08M -130.25M
Net income -17.54M -32.12M -50.26M -26.08M -183.85M
Selling general administrative 8.57M - 11.55M 9.77M 4.64M
Gross profit -0.23M -0.23M -0.27M -0.24M -0.23M
Reconciled depreciation 0.23M - 0.23M 0.23M 0.23M
Ebit -17.21M -32.18M -45.96M -23.92M -138.03M
Ebitda -16.98M -31.95M -45.69M -23.68M -137.80M
Depreciation and amortization 0.23M 0.23M 0.27M 0.24M 0.23M
Non operating income net other - - - 3.33M -
Operating income -18.07M -32.18M -45.08M -27.25M -138.05M
Other operating expenses 18.07M 32.18M 45.08M 27.25M 138.05M
Interest expense 0.33M 2.89M 4.30M 2.16M 0.56M
Interest income 0.85M - 0.56M 0.04M 0.02M
Net interest income 0.52M - -3.74M -2.12M -0.54M
Income tax expense - -0.23M 4.30M -3.29M 0.56M
Total revenue 0.00M - 0.00M 0.00M 0.00M
Total operating expenses 17.84M 31.95M 45.08M 27.25M 138.05M
Cost of revenue 0.23M 0.23M 0.27M 0.24M 0.23M
Total other income expense net 0.52M 0.06M -5.18M 1.17M 7.80M
Net income from continuing ops -17.54M - -50.26M -26.08M -130.25M
Net income applicable to common shares - - -50.26M -26.08M -183.85M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 21.56M 25.21M 35.10M 20.11M 6.05M
Intangible assets 0.18M 0.41M 0.64M 0.87M 1.10M
Other current assets 1.05M 0.20M 0.10M 0.14M 0.09M
Total liab 2.55M 9.70M 19.76M 16.44M 1.00M
Total stockholder equity 19.01M 15.51M 15.34M 3.67M 5.05M
Other current liab 2.20M 0.00M 5.34M 4.13M 1.00M
Common stock 0.01M 0.01M 0.00M 0.00M 0.00M
Capital stock 0.01M - 0.00M 0.00M 0.00M
Retained earnings -352.14M -334.23M -301.23M -250.97M -224.89M
Other liab - - - 0.05M -
Good will 0.35M 0.35M 0.35M 0.35M 0.35M
Other assets - - - 0.00M -
Cash 17.54M 23.84M 19.46M 18.64M 4.51M
Total current liabilities 2.27M 9.35M 14.49M 4.17M 1.00M
Current deferred revenue - -3.59M - - -
Net debt -17.19M -17.73M -5.04M -6.38M -4.51M
Short term debt 0.07M 5.76M 9.15M 0.04M -
Short long term debt - - 9.11M - -
Short long term debt total 0.35M 6.11M 14.42M 12.26M -
Other stockholder equity 371.15M 349.73M 316.39M 254.64M 229.93M
Property plant equipment - - 0.08M 0.12M -
Total current assets 20.70M 24.05M 34.04M 18.78M 4.61M
Net tangible assets - - 14.36M 2.46M 3.61M
Short term investments - - 14.48M - -
Net receivables 2.10M - - - -
Long term debt - - 5.23M 12.14M -
Accounts payable 2.20M 3.59M 3.48M 2.44M 1.00M
Accumulated other comprehensive income 0.00M 0.00M 0.18M - -
Common stock total equity - - - 0.00M 0.00M
Retained earnings total equity - - - -250.97M -
Non currrent assets other 0.00M - - 0.00M -
Non current assets total 0.86M 1.16M 1.06M 1.33M 1.44M
Capital lease obligations 0.35M - 0.09M 0.13M -
Long term debt total - - - 12.14M -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments 0.00M - -14.30M -14.30M -14.30M
Change to liabilities - - 1.03M 2.80M -0.26M
Total cashflows from investing activities - - -14.30M -14.30M -14.30M
Net borrowings -5.85M - - 14.61M -1.39M
Total cash from financing activities 12.73M 17.80M 55.37M 33.12M 14.93M
Change to operating activities - - -1.30M 1.30M 0.28M
Net income -17.54M -32.12M -50.26M -26.08M -130.25M
Change in cash -6.30M 4.38M 0.82M 14.13M 4.47M
Begin period cash flow 23.84M 19.46M 18.64M 4.51M 0.04M
End period cash flow 17.54M 23.84M 19.46M 18.64M 4.51M
Total cash from operating activities -19.03M -27.95M -40.25M -18.99M -10.45M
Issuance of capital stock 15.67M - 55.37M 18.51M 15.63M
Depreciation 0.23M 0.23M 0.23M 0.23M 0.23M
Dividends paid 369465.00M 0.89M - - 53.60M
Change to account receivables -2.10M - - - -
Sale purchase of stock - - - 18.51M -
Other cashflows from financing activities 2.90M 14.53M 0.00M 18.51M 0.69M
Change to netincome - - 9.87M 2.52M 119.55M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Cash flows other operating - - - 1.44M -
Cash and cash equivalents changes - - - 14.13M -
Change in working capital -4.40M -0.09M -0.27M 2.75M 0.02M
Stock based compensation 2.47M 4.66M 6.38M 6.19M 3.02M
Other non cash items 0.21M -0.63M 1037.12M -2.08M 124.87M
Free cash flow -19.03M -27.95M -40.25M -18.99M -10.45M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
BIVI
Biovie Inc		 0.12
9.92%		 1.33 - - - 0.62 -11.66
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Biovie Inc

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

680 W. Nye Lane, Carson City, NV, United States, 89703

775 888 3162

https://bioviepharma.com

13

Name Title Year Born
Mr. Cuong Viet Do M.B.A., MBA Pres, CEO & Director 1966
Ms. Joanne Wendy Kim CPA CFO, Treasurer & Corp. Sec. 1955
Dr. Joseph M. Palumbo M.D. Chief Medical Officer 1960
Dr. Penelope Markham Ph.D. Exec. VP of Liver Disease R&D 1966
Ms. Denise Smith Sr. VP of Manufacturing & Devel. NA
Dr. Christopher L. Reading Ph.D. Exec. VP of Neuroscience R&D 1948
Mr. Clarence N. Ahlem Exec. VP of Neuroscience Product Devel. 1955
Ms. Sarah Overton Hoit Chief Social Impact Officer 1967
Mr. Cuong Viet Do M.B.A. President, CEO & Director 1966
Ms. Joanne Wendy Kim CPA CFO, Treasurer & Corporate Secretary 1955

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…